Cell Signaling Technology Logo - Extra Large
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Eosinophil peroxidase (F3C2H) Rabbit mAb #98757

Filter:
  • WB
  • IHC

    Product Specifications

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 81, 45-50, 20-25
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Eosinophil peroxidase (F3C2H) Rabbit mAb recognizes endogenous levels of total Eosinphil peroxidase protein. This antibody recognizes the full-length precursor, heavy chain, and light chain subunits of human Eosinophil peroxidase protein. Non-specific nuclear staining was observed in human testis and limited human tumors by immunohistochemistry.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn585 of human Eosinphil peroxidase protein.

    Background

    Eosinophil peroxidase (EPX), also known as EPO, is a cationic protein stored in the secondary granulocytes of eosinophils (1-4). Unprocessed precursor EPX is an 80 kDa monomeric glycoprotein, which consists of two polypeptides linked by disulfide bonds: ~55 kDa heavy and ~15 kDa light chain (1-3, 6). In response to allergens or parasitic infection, eosinophils are recruited to affected tissues, where EPX catalyzes the formation of reactive oxidants lethal to tissue-invading parasites (1-4). In the tumor microenvironment of some breast cancers, eosinophils accumulate near blood vessels and infiltrate hypoxic regions, where EPX is released in high quantities by infiltrating immune cells (5). EPX may contribute to cancer progression by augmenting pro-tumorigenic collagen production and angiogenesis, making it a potential therapeutic target in breast cancer therapy (5).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.